Abdominal aortic aneurysm: Novel mechanisms and therapies

Current Opinion in Cardiology

Volumn 30, Issue 6, 2015, Pages 566-573

  Davis, Frank M ^a,b   Rateri, Debra L ^b   Daugherty, Alan ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Abdominal aortic aneurysm; Extracellular matrix fragmentation; Genetics; Inflammation; MicroRNA

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; INTERLEUKIN 1; INTERLEUKIN 17; REACTIVE OXYGEN METABOLITE; SORTILIN; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; GENETIC MARKER;

ABDOMINAL AORTA ANEURYSM; EXTRACELLULAR MATRIX; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; INFLAMMATORY CELL; LEUKOCYTE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; AORTIC ANEURYSM, ABDOMINAL; DIAGNOSTIC IMAGING; GENE THERAPY; GENETIC MARKER; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PROCEDURES;

AORTIC ANEURYSM, ABDOMINAL; DIAGNOSTIC IMAGING; GENETIC MARKERS; GENETIC THERAPY; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 84944072954     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000216     Document Type: Review

References (75)

1. Golledge J, Muller J, Daugherty A, et al. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006; 26:2605-2613.
2. Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 2011; 41 (Suppl 1):S1-S58.
3. Anjum A, Powell JT. Is the incidence of abdominal aortic aneurysm declining in the 21st century? Mortality and hospital admissions for England & Wales and Scotland. Eur J Vasc Endovasc Surg 2012; 43:161-166.
4. Sidloff D, Stather P, Dattani N, et al. Aneurysm global epidemiology study: public health measures can further reduce abdominal aortic aneurysm mortality. Circulation 2014; 129:747-753.
5. Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database Syst Rev 2014; 1:CD010447.
6. Joergensen TM, Houlind K, Green A, et al. Abdominal aortic diameter is increased in males with a family history of abdominal aortic aneurysms: results from the Danish VIVA-trial. Eur J Vasc Endovasc Surg 2014; 48:669-675.
7. Morris DR, Biros E, Cronin O, et al. The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-Analysis. Heart 2014; 100:295-302.
8. JonesGT, Bown MJ, Gretarsdottir S, et al. A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. Hum Mol Genet 2013; 22:2941-2947.
9. Biros E, Norman PE, Jones GT, et al. Meta-Analysis of the association between single nucleotide polymorphisms in TGF-beta receptor genes and abdominal aortic aneurysm. Atherosclerosis 2011; 219:218-223.
10. Gretarsdottir S, Baas AF, Thorleifsson G, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet 2010; 42:692-697.
11. Elmore JR, Obmann MA, Kuivaniemi H, et al. Identification of a genetic variant associated with abdominal aortic aneurysms on chromosome 3p12.3 by genome wide association. J Vasc Surg 2009; 49:1525-1531.
12. Bown MJ, Jones GT, Harrison SC, et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein1 Am J Hum Genet 2011; 89:619-627.
13. Galora S, Saracini C, Pratesi G, et al. Association of rs1466535 LRP1 but not rs3019885 SLC30A8 and rs6674171 TDRD10 gene polymorphisms with abdominal aortic aneurysm in Italian patients. J Vasc Surg 2014; 61:787-792.
14. Bradley DT, Hughes AE, Badger SA, et al. A variant in LDLR is associated with abdominal aortic aneurysm. Circ Cardiovasc Genet 2013; 6:498-504.
15. Ryer EJ, Ronning KE, Erdman R, et al. The potential role of DNA methylation in abdominal aortic aneurysms. Int J Mol Sci 2015; 16:11259-11275.
16. Toghill BJ, Saratzis A, Harrison SC, et al. The potential role of DNA methylation in the pathogenesis of abdominal aortic aneurysm. Atherosclerosis 2015; 241:121-129.
17. Sidloff DA, Stather PW, Choke E, et al. A systematic review and meta-Analysis of the association between markers of hemostasis and abdominal aortic aneurysm presence and size. J Vasc Surg 2014; 59:528-535.
18. Stather PW, Sidloff DA, Dattani N, et al. Meta-Analysis and meta-regression analysis of biomarkers for abdominal aortic aneurysm. Br J Surg 2014; 101:1358-1372.
19. Davis FM, Rateri DL, Daugherty A. Mechanisms of aortic aneurysm formation: translating preclinical studies into clinical therapies. Heart 2014; 100:1498-1505.
20. Michineau S, Franck G, Wagner-Ballon O, et al. Chemokine (C-X-C motif) receptor4 blockade by AMD3100 inhibits experimental abdominal aortic aneurysm expansion through anti-inflammatory effects. Arterioscler Thromb Vasc Biol 2014; 34:1-10.
21. Mellak S, Ait-Oufella H, Esposito B, et al. Angiotensin II mobilizes spleen monocytes to promote the development of abdominal aortic aneurysm in Apoe-/-mice. Arterioscler Thromb Vasc Biol 2015; 35:378-388.
22. Xiao J, Angsana J, Wen J, et al. Syndecan-1 displays a protective role in aortic aneurysm formation by modulating T cell-mediated responses. Arterioscler Thromb Vasc Biol 2012; 32:386-396.
23. Yin M, Zhang J, Wang Y, et al. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2010; 30:1825-1831.
24. Ait-Oufella H, Wang Y, Herbin O, et al. Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. Arterioscler Thromb Vasc Biol 2013; 33:2374-2379.
25. Yodoi K, Yamashita T, Sasaki N, et al. Foxp3+ regulatory T cells play a protective role in angiotensin II-induced aortic aneurysm formation in mice. Hypertension 2015; 65:889-895.
26. Meng X, Yang J, Zhang K, et al. Regulatory T cells prevent angiotensin IIinduced abdominal aortic aneurysm in apolipoprotein E knockout mice. Hypertension 2014; 64:875-882.
27. Obama T, Tsuji T, Kobayashi T, et al. Epidermal growth factor receptor inhibitor protects against abdominal aortic aneurysm in a mouse model. Clin Sci (Lond) 2015; 128:559-565.
28. Johnston WF, Salmon M, Su G, et al. Genetic and pharmacologic disruption of interleukin-1 beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2013; 33:294-304.
29. Wei Z, Wang Y, Zhang K, et al. Inhibiting the Th17/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2014; 34:2429-2438.
30. Usui F, Shirasuna K, Kimura H, et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol 2015; 35:127-136.
31. Doyle AJ, Redmond EM, Gillespie DL, et al. Differential expression of Hedgehog/Notch and transforming growth factor-b in human abdominal aortic aneurysms. J Vasc Surg 2015; 62:464-470.
32. Wang Y, Ait-Oufella H, Herbin O, et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin IIinfused mice. J Clin Invest 2010; 120:422-432.
33. Dai X, Shen J, Priyanka Annam N, et al. SMAD3 deficiency promotes vessel wall remodeling, collagen fiber reorganization and leukocyte infiltration in an inflammatory abdominal aortic aneurysm mouse model. Sci Rep 2015; 5:10180.
34. Krishna SM, Seto SW, Jose RJ, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol 2015; 35:389-398.
35. Hans CP, Koenig SN, Huang N, et al. Inhibition of Notch1 signaling reduces abdominal aortic aneurysm in mice by attenuating macrophage-mediated inflammation. Arterioscler Thromb Vasc Biol 2012; 32:3012-3023.
36. Zheng YH, Li FD, Tian C, et al. Notch gamma-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One 2013; 8:e83310.
37. Cheng J, Koenig SN, Kuivaniemi HS, et al. Pharmacological inhibitor of notch signaling stabilizes the progression of small abdominal aortic aneurysm in a mouse model. J Am Heart Assoc 2014; 3:e001064.
38. Lei XF, Kim-Kaneyama JR, Arita-Okubo S, et al. Identification of Hic-5 as a novel scaffold for the MKK4/p54 JNK pathway in the development of abdominal aortic aneurysms. J Am Heart Assoc 2014; 3:e000747.
39. Kigawa Y, Miyazaki T, Lei XF, et al. NADPH oxidase deficiency exacerbates angiotensin II-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2014; 34:2413-2420.
40. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005; 4:664-672.
41. Zhao L, Moos MP, Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Med 2004; 10:966-973.
42. Ahluwalia N, Lin AY, Tager AM, et al. Inhibited aortic aneurysm formation in BLT1deficient mice. J Immunol 2007; 179:691-697.
43. Cao RY, Adams MA, Habenicht AJ, et al. Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat 2007; 84:34-42.
44. Bhamidipati CM, Whatling CA, Mehta GS, et al. 5-Lipoxygenase pathway in experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2014; 34:2669-2678.
45. Lu H, Rateri DL, Bruemmer D, et al. Involvement of the renin-Angiotensin system in abdominal and thoracic aortic aneurysms. Clin Sci 2012; 123:531-543.
46. Kaschina E, Schrader F, Sommerfeld M, et al. Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens 2008; 26:2361-2373.
47. Fujiwara Y, Shiraya S, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 2008; 22:703-708.
48. Seto SW, Krishna SM, Moran CS, et al. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-Edeficient mouse model. Clin Sci (Lond) 2014; 127:123-134.
49. Liu S, Xie Z, Daugherty A, et al. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arterioscler Thromb Vasc Biol 2013; 33:1568-1579.
50. Golledge J. Is there a new target in the renin-Angiotensin system for aortic aneurysm therapy? Arterioscler Thromb Vasc Biol 2013; 33:1456-1457.
51. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370:455-465.
52. Wang Q, Liu Z, Ren J, et al. Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ Res 2015; 116:600-611.
53. Muratoglu SC, Belgrave S, Hampton B, et al. LRP1 protects the vasculature by regulating levels of connective tissue growth factor and HtrA1. Arterioscler Thromb Vasc Biol 2013; 33:2137-2146.
54. Davis FM, Rateri DL, Balakrishnan A, et al. Smooth muscle cell deletion of low-density lipoprotein receptor-related protein 1 augments angiotensin II-induced superior mesenteric arterial and ascending aortic aneurysms. Arterioscler Thromb Vasc Biol 2015; 35:155-162.
55. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin 2004; 20:419-432.
56. Lohoefer F, Reeps C, Lipp C, et al. Quantitative expression and localization of cysteine and aspartic proteases in human abdominal aortic aneurysms. Exp Mol Med 2014; 46:e95.
57. Lv BJ, Lindholt JS, Wang J, et al. Plasma levels of cathepsins L, K, and V and risks of abdominal aortic aneurysms: a randomized population-based study. Atherosclerosis 2013; 230:100-105.
58. Sun J, Sukhova GK, Zhang J, et al. Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2012; 32:15-23.
59. Wang J, Sukhova GK, Liu J, et al. Cathepsin G deficiency reduces periaortic calcium chloride injury-induced abdominal aortic aneurysms in mice. J Vasc Surg 2014. [Epub ahead of print]
60. Moran CS, McCann M, Karan M, et al. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111:3119-3125.
61. Moran CS, Jose RJ, Biros E, et al. Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. Arterioscler Thromb Vasc Biol 2014; 34:2609-2616.
62. Maegdefessel L, Azuma J, Toh R, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 2012; 122:497-506.
63. Maegdefessel L, Spin JM, Raaz U, et al. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat Commun 2014; 5:5214.
64. Maegdefessel L, Azuma J, Toh R, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-Augmented expansion. Sci Transl Med 2012; 4:122ra22.
65. Kim CW, Kumar S, Son DJ, et al. Prevention of abdominal aortic aneurysm by antimicroRNA-712 or antimicroRNA-205 in angiotensin II-infused mice. Arterioscler Thromb Vasc Biol 2014; 34:1412-1421.
66. Cheuk BL, Cheng SW. Identification and characterization of microRNAs in vascular smooth muscle cells from patients with abdominal aortic aneurysms. J Vasc Surg 2014; 59:202-209.
67. Zampetaki A, Attia R, Mayr U, et al. Role of miR-195 in aortic aneurysmal disease. Circ Res 2014; 115:857-866.
68. Spear R, Boytard L, Blervaque R, et al. Adventitial tertiary lymphoid organs as potential source of microRNA biomarkers for abdominal aortic aneurysm. Int J Mol Sci 2015; 16:11276-11293.
69. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11:860-872.
70. Takagi H, Manabe H, Kawai N, et al. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-Analysis. Interact Cardiovasc Thorac Surg 2009; 9:437-440.
71. Dilme JF, Bellmunt S, Camacho M, et al. Influence of cardiovascular risk factors on levels of matrix metalloproteinases 2 and 9 in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2014; 48:374-381.
72. Mata KM, Tefe-Silva C, Floriano EM, et al. Interference of doxycycline pretreatment in a model of abdominal aortic aneurysms. Cardiovasc Pathol 2015; 24:110-120.
73. Meijer CA, Stijnen T, Wasser MN, et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 2013; 159:815-823.
74. Kortekaas KE, Meijer CA, Hinnen JW, et al. ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm. PLoS One 2014; 9:e111952.
75. Kristensen KE, Torp-Pedersen C, Gislason GH, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study. Arterioscler Thromb Vasc Biol 2015; 35:733-740.